The United States has approved weight-loss drugs since 1959, and it has also withdrawn four of them. Most lists of "FDA-approved weight-loss drugs" give only the survivors. This page puts both in one dated register: every approval still standing, with its date and application number from Drugs@FDA, and every withdrawal, with the Federal Register notice that ended it. It ranks nothing and recommends nothing.
Everything below was read from FDA's Drugs@FDA database, current labels and the Federal Register on 20 November 2026. The individual pages linked in each row carry the trial figures and prices; this page carries the dates.
Approved and still standing: long-term use
| Product | Molecule and form | Original approval (Drugs@FDA) | Application | Who the label covers |
|---|---|---|---|---|
| Xenical | Orlistat 120 mg, capsule | 23 April 1999 | NDA 020766 | Adults; prescription |
| Alli | Orlistat 60 mg, capsule | 7 February 2007 | NDA 021887 | Adults; the only over-the-counter weight drug |
| Qsymia | Phentermine with extended-release topiramate, capsule | 17 July 2012 | NDA 022580 | Adults and children 12 and older |
| Contrave | Naltrexone with bupropion, tablet | 10 September 2014 | NDA 200063 | Adults |
| Saxenda | Liraglutide 3 mg, daily injection | 23 December 2014 | NDA 206321 | Adults, and children 12+ over 60 kg; generic liraglutide versions rated equivalent are on the Saxenda page |
| Imcivree | Setmelanotide, daily injection | 25 November 2020 | NDA 213793 | Only obesity from acquired hypothalamic damage, Bardet-Biedl syndrome, or confirmed POMC, PCSK1 or LEPR gene variants (label of 1 April 2026) |
| Wegovy (injection) | Semaglutide, weekly injection | 4 June 2021 | NDA 215256 | Adults and children 12+; also cardiovascular risk reduction in adults with heart disease |
| Zepbound | Tirzepatide, weekly injection | 8 November 2023 | NDA 217806 | Adults; also moderate to severe obstructive sleep apnoea with obesity |
| Wegovy tablet | Oral semaglutide, daily tablet | 22 December 2025 | NDA 218316 | Adults |
| Foundayo | Orforglipron, daily tablet | 1 April 2026 | NDA 220934 | Adults |
Drugs@FDA lists three products under Wegovy's injection application on 20 November 2026: Wegovy, Wegovy FlexTouch and Wegovy HD. Zepbound's lists Zepbound, Zepbound (autoinjector) and Zepbound KwikPen. A new presentation of an approved drug usually arrives as a supplement to the same application, not as a new approval, which is why the dates above are the first approval of the molecule for weight.
Approved and still standing: short-term use only
Four older appetite suppressants are still approved, each limited by its label to "a few weeks" of use. They are listed with their label records on the weight-loss pills register:
- Phentermine (Adipex-P, ANDA 085128, 22 October 1980 in Drugs@FDA; the molecule is older), Schedule IV.
- Diethylpropion (Tenuate, NDA 011722, 6 August 1959), Schedule IV — the oldest approval in this register.
- Benzphetamine (Didrex, 26 October 1960) and phendimetrazine (oldest Drugs@FDA records 1977 and 1979), both Schedule III.
Withdrawn: the four approvals that did not last
| Drug | Brand | Approved | FDA asked for withdrawal | Reason, as the FDA's notice states it | Approval formally withdrawn |
|---|---|---|---|---|---|
| Fenfluramine | Pondimin, Ponderex | 14 June 1973 | Announced 15 September 1997 | "associated with valvular heart disease" | Pondimin determined withdrawn for safety in a notice of 29 September 2015 (80 FR 58490) |
| Dexfenfluramine | Redux | (record no longer in Drugs@FDA) | 1997, same announcement | "associated with valvular heart disease" | 30 January 2007 (72 FR 4270), at the maker's request |
| Sibutramine | Meridia | 22 November 1997 | 7 October 2010 | Increased "risk of heart attack and stroke" in the SCOUT outcomes trial | 21 December 2010 (75 FR 80061) |
| Lorcaserin | Belviq; Belviq XR | 27 June 2012; XR 15 July 2016 | 13 February 2020 | "increased occurrence of cancer" in a safety trial | 17 September 2020 (85 FR 58063); generics barred, 4 March 2021 (86 FR 12697) |
In every case the maker withdrew the product at the FDA's request rather than through a contested proceeding. The notices record each company waiving its opportunity for a hearing. The formal end of an application can lag the market withdrawal by months or, for fenfluramine and dexfenfluramine, by a decade: the drugs left pharmacies in 1997, but the applications themselves were closed out in 2007 and 2015.
Fen-phen, 1997
"Fen-phen" was never one approved product. It was fenfluramine and phentermine prescribed together. The FDA issued a health advisory on the combination on 8 July 1997 and announced the withdrawal of fenfluramine and dexfenfluramine on 15 September 1997, as the 2007 Redux notice recounts. Phentermine was not withdrawn and is still approved for short-term use. In 1998 the FDA proposed adding "all drug products containing fenfluramine hydrochloride" to the list of drugs that may not be compounded because they were found unsafe, according to the 2015 notice.
Fenfluramine later returned for a different disease. On 25 June 2020 the FDA approved it as Fintepla (NDA 212102), an oral solution for seizures associated with Dravet syndrome, a rare childhood epilepsy. The DEA then removed fenfluramine from the controlled-substance schedules by a final rule published 23 December 2022 (87 FR 78857). It carries no weight-loss approval.
Sibutramine, 2010
The withdrawal followed the SCOUT trial (James et al., New England Journal of Medicine, 2010; PMID 20818901), which randomised 9,804 overweight or obese adults aged 55 or over with existing cardiovascular disease, type 2 diabetes or both. Over a mean 3.4 years of treatment, the primary outcome — non-fatal heart attack, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death — occurred in 11.4% on sibutramine against 10.0% on placebo (hazard ratio 1.16, 95% CI 1.03 to 1.31). Non-fatal heart attacks were 4.1% against 3.2%, non-fatal strokes 2.6% against 1.9%; cardiovascular death and death from any cause were not increased. The weight difference bought with that risk was small: after a 2.6 kg loss in the open lead-in that everyone took, the sibutramine group lost a mean 1.7 kg more. The FDA's notice states that, after an advisory committee reviewed SCOUT on 15 September 2010, the agency found the benefits "no longer outweigh the risks in any identifiable patient population."
Lorcaserin, 2020
Belviq's withdrawal began with a trial designed to test its heart safety, CAMELLIA-TIMI 61. In January 2019 the FDA warned that the trial's results showed a possible increased risk of cancer; on 13 February 2020 it asked Eisai to withdraw both products, and the applications were withdrawn on 17 September 2020, according to the Federal Register notice. The FDA's own reviewers set out their reasoning in the New England Journal of Medicine (Sharretts et al., 2020; PMID 32905671). A later meta-analysis of four randomised trials counted 476 cancers among 10,342 people on lorcaserin and 438 among 9,429 on placebo, a relative risk of 1.08 (95% CI 0.96 to 1.23), with the result driven by CAMELLIA and more lung and pancreatic cancers in the lorcaserin group (de Andrade Mesquita et al., Obesity Reviews, 2021; PMID 33258543). The authors concluded that the evidence "does not confirm" the increased risk but suggests a trend. The two readings are not in conflict on the facts: the FDA withdrew on a signal it judged not worth the modest weight benefit; the pooled analysis could not confirm or exclude that signal.
What the pattern shows, and what it does not
- Three of the four withdrawals came from evidence that arrived after approval. Sibutramine and lorcaserin were both withdrawn on the strength of large outcome trials run after they were on the market, in older or higher-risk populations than the original trials. The valve findings on fenfluramine came from post-marketing reports. This is how the post-approval safety system is supposed to work, and it is also why the newest drugs in the first table have the shortest safety record.
- Today's GLP-1 labels carry outcome data the withdrawn drugs did not. Wegovy's label includes a cardiovascular risk-reduction indication from its SELECT outcome trial, and the label wording quoted in the facts above is a change of phrasing, not of evidence. Each GLP-1 label also carries its own boxed warning about thyroid C-cell tumours from rodent studies, covered on our thyroid cancer page.
- A withdrawal does not mean everyone who took the drug was harmed, and an approval does not mean a drug is safe for everyone. The labels name who should not take each product; that judgement belongs with a prescriber.
What this register does not cover
- Drugs approved for other conditions and used off-label for weight, such as Ozempic, Mounjaro, metformin or topiramate alone. Their status is on the weight-loss injections register and their own pages.
- Compounded and unapproved products, which are not FDA-approved by definition; see compounded semaglutide.
- Drugs still in trials or awaiting a decision, such as CagriSema and retatrutide, which are on the new weight-loss drugs tracker.
- Devices. Some weight-loss devices are cleared or authorised by the FDA under a separate pathway; they are not drugs and are not listed here.
What this page does not do
It does not rank these drugs, compare their effectiveness or suggest which one anyone should use. The dates come from FDA records read on the day stated; where a record could not be found (Redux's original approval no longer appears in Drugs@FDA), the page says so rather than filling the gap from memory.
Sources
- FDA, Drugs@FDA database (via the openFDA drugsfda API), application records for NDA 020766, 021887, 022580, 200063, 206321, 213793, 215256, 217806, 218316, 220934, 020632 and 212102, and ANDA 085128 — read 20 November 2026.
- Current labels (openFDA label API): Imcivree (effective 1 April 2026), Saxenda (26 January 2024 and 25 February 2026), Zepbound (28 August 2026), Wegovy — read 20 November 2026.
- Federal Register: 85 FR 58063 (Belviq, 17 September 2020); 86 FR 12697 (Belviq, 4 March 2021); 75 FR 80061 (Meridia, 21 December 2010); 72 FR 4270 (Redux, 30 January 2007); 80 FR 58490 (Pondimin, 29 September 2015); 87 FR 42979 and 87 FR 78857 (DEA, fenfluramine decontrol) — all read 20 November 2026.
- James WP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905–17. doi:10.1056/NEJMoa1003114.
- Sharretts J et al. Cancer risk associated with lorcaserin — the FDA's review of the CAMELLIA-TIMI 61 trial. N Engl J Med 2020;383:1000–1002. doi:10.1056/NEJMp2003873.
- de Andrade Mesquita L et al. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. Obes Rev 2021;22:e13170. doi:10.1111/obr.13170.
